Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on average 50.3 lb (22.8 kg) while those treated with semaglutide lost 33.1 lb (15 kg), translating to a 47% greater relative weight loss with tirzepatide.
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Analysts say Eli Lilly may have a future blockbuster drug on its hands: An experimental pill designed to lower ... so lifestyle changes such as diet or exercise have no effect, Ruth Gimeno ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback